Type 2 diabetes mellitus. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: The intervention group will take Cabergolin (produced by Iran hormone company), 0.25 mg twice a week during first 2 weeks and they will take Cabercolin 0.5 mg twice a week for next 12
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: A type 2 diabetic patient with a history of at least 3 months receiving metformin at a dose of 2 g / day Age from 30 to 65 years HbA1C levels in the range of 7- 8.5 Obtaining Conscious Consent from all Participants involved in the Study
Exclusion criteria
Exclusion criteria: Pregnancy The presence of other diseases (cardiovascular, kidney, liver, lung, thyroid and pituitary diseases) smoking Taking herbal remedies Taking other diabetes controller drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fast blood sugar. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;2-hour postprandial blood sugar. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;HbA1C. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cholestrol. Timepoint: Basline and 3 months after the treatment. Method of measurement: Blood Test.;TG. Timepoint: Basline and 3 months after the treatment. Method of measurement: Blood Test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Akbar Aliasgharzadeh
Tabriz University of Medical Sciences
Outcome results
None listed